Analyst Report: COO

1. EXECUTIVE SUMMARY

Shares of The Cooper Companies, Inc. (COO) plunged -22.09% over the past week, suffering a severe technical and fundamental breakdown to hit a 52-week low of $51.01. The precipitous drop was triggered by a "triple-shock" fiscal Q3 2026 earnings release on September 9, 2026. Management announced a top-line revenue miss, slashed forward guidance due to prolonged U.S. channel inventory destocking in its core CooperVision unit, and concluded a highly anticipated 9-month strategic review by opting to retain its CooperSurgical business rather than selling it. This decision erased any anticipated sum-of-the-parts premium. Despite generating a record $273 million in free cash flow and authorizing a massive $3 billion share buyback program, growth investors aggressively capitulated. The long-term thesis has now pivoted from a catalyst-driven spin-off story to a "show-me" value and execution play.

2. THE CATALYST (CRITICAL)

The massive selloff was initiated by the Q3 2026 earnings report and strategic update released after market close on Wednesday, September 9, 2026. The news triggered a 14.7% gap down on Thursday, September 10, the worst single-day performance in the S&P 500.

Specific triggers included:

• Revenue Miss & Stalled Growth: Q3 revenue of $1.066 billion missed the $1.098 billion consensus. More concerningly, CooperVision (which accounts for ~67% of total sales) posted $717 million in revenue—representing 0% organic growth year-over-year.
• Guidance Cut: Full-year fiscal 2026 EPS guidance was reduced to $4.51-$4.55 (down from the prior $4.58-$4.66 and below the $4.63 consensus). Q4 revenue guidance was also lowered to $1.057B-$1.080B, missing the $1.106B Street estimate. Management explicitly blamed "proactive U.S. channel inventory reductions" which will persist into Q4.
• Strategic Review Disappointment: Since December 2025, investors had bid up the stock anticipating a sale or spin-off of the CooperSurgical unit (fertility and women's health). The Board concluded this review on September 9, stating they would retain the business due to a "valuation disconnect" caused by competitive headwinds and recent fertility litigation settlements.
• Analyst Downgrades: Wall Street reacted swiftly. Bank of America downgraded the stock from Buy to Neutral (cutting its price target from $80 to $65), Piper Sandler slashed its target from $86 to $59, and Needham cut its target from $86 to $73.
• Legal Scrutiny: Following the drop, shareholder rights firm Hagens Berman (HBSS) launched an investigation on September 14, 2026, probing whether management misled investors during the Q2 call when they guided for 3.5% to 4.5% full-year organic revenue growth for CooperVision.

3. COMPANY PROFILE

• Official Company Name: The Cooper Companies, Inc.
• Core Business: A leading global medical device manufacturer operating through two primary segments. CooperVision is a top-tier manufacturer of contact lenses (daily silicone hydrogel, torics, multifocals, and myopia management), controlling roughly 25% of the U.S. market. CooperSurgical focuses on women's healthcare, fertility, and reproductive devices, including Paragard, the only hormone-free IUD available in the U.S.
• Market Capitalization: ~$10.25 billion to $12.4 billion (reflecting the recent $1.7+ billion market cap wipeout).
• Sector: Healthcare / Medical Devices.
• Key Competitors: Johnson & Johnson Vision, Alcon, and Bausch + Lomb (Vision segment).
• Recent Performance Context: Trading near 52-week lows of $51.01, significantly down from its 52-week high of $89.83. The stock is down ~22.6% YTD.

4. DEEP DIVE ANALYSIS

Fundamentals vs. Overreaction: The violent price action reflects a total reset of the shareholder base rather than an existential crisis for the underlying business. Growth investors holding the stock for a CooperSurgical divestiture catalyst have exited. However, underneath the headline misses, the company delivered a non-GAAP EPS of $1.15 (beating the $1.12 estimate) marking its 11th consecutive quarterly earnings beat. Furthermore, free cash flow (FCF) surged 66% year-over-year to a record $273 million for the quarter.

The "Conglomerate Discount": By walking away from the CooperSurgical sale, the Board effectively forced the market to apply a "conglomerate discount" to the stock. The surgical unit is currently weighed down by incoming competition for its Paragard IUD and recent fertility litigation. Without a clean spin-off, the slower-growing, litigation-heavy surgical segment will continue to dilute the valuation multiple of the highly profitable CooperVision business.

Bull Case vs. Bear Case:

• Bull Case: The fundamental floor is heavily supported by valuation and capital return. At current levels, the stock trades at approximately 12-13x forward earnings. To pacify investors, the Board authorized a massive $3.0 billion share repurchase plan—equating to nearly 30% of the company's current market cap. If management executes this aggressively alongside their record FCF generation, downside is highly capped.
• Bear Case: The "U.S. channel destocking" narrative in CooperVision may be masking deeper market share losses to J&J or Alcon. If Q4 reveals that end-market consumption is actually declining, the stock will face further multiple compression. Additionally, upcoming changes to the Global Intangible Low-Taxed Income (GILTI) tax could push the company's effective tax rate from ~15.5% to ~17.5% in FY2027, eating into bottom-line growth.

5. TECHNICAL SNAPSHOT

• Key Support / Resistance: The stock cleanly broke through multiple technical floors, finding initial support at the new 52-week low of $51.01. Immediate resistance is now firmly established at the pre-gap level of ~$63.50, with the 200-day moving average trailing significantly higher at $69.70.
• Volume Analysis: The selloff was driven by extreme institutional capitulation. Volume on September 9/10 exploded to roughly 8.3M–9.2M shares, approximately 4x to 12x the normal average daily volume of ~2.3 million shares.
• Chart Patterns: The stock formed a severe "breakaway gap" down on the daily chart. While the stock is heavily oversold on the Relative Strength Index (RSI), breakaway gaps of this magnitude on heavy volume typically require months of sideways consolidation to build a new base.

6. RISK FACTORS

• Prolonged Channel Destocking: Management indicated the destocking will bleed into Q4. Any indication during the next earnings call that inventory gluts have not cleared will severely damage management credibility.
• Litigation Overhang: The newly announced Hagens Berman investigation regarding potential securities law violations (specifically surrounding Q2 organic growth guidance vs. Q3 reality) could evolve into a costly class-action lawsuit.
• Paragard Market Share: New non-hormonal IUD competitors threaten the moat of CooperSurgical's highest-margin product.
• Upcoming Catalysts: Investors will closely monitor the opening of "The Vision Centre" (global R&D hub) on September 23, 2026, for product pipeline updates. The ultimate litmus test will be Q4 2026 Earnings, currently estimated for December 3, 2026.

7. ACTIONABLE OUTLOOK

• Short-Term (1-2 weeks): Expect the stock to stabilize and consolidate in the $51.00 – $55.00 range. The sheer size of the $3 billion buyback program acts as an effective put option against further cascading momentum. We anticipate dead-cat bounces but no rapid V-shaped recovery due to broken technicals.
• Medium-Term (1-3 months): The stock is trapped in the "penalty box." Valuation multiples will remain compressed until the Q4 print in December 2026 proves that U.S. channel destocking was a temporary reset and not a structural loss of market share.
• Long-Term Thesis: The thesis has fundamentally shifted. COO is no longer a corporate restructuring / spin-off play; it is a cash-flow yield and capital return story. Patient value investors (like current top holders T. Rowe Price and Diamond Hill) will likely utilize the depressed levels to accumulate. At current valuations, the underlying free cash flow generation makes COO highly attractive for long-horizon capital, provided they can stomach near-term operational turbulence.